TEVA
TEVA
US8816242098
Teva Pharmaceutical Industries
Loading chart...
Elevated Business & Solvency Risk

Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 55/100).

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.8x).

Beta (Market Relation)
0.82x
Defensive
Volatility (5Y p.a.)
42.8% p.a.
5-Year Horizon
Max Drawdown (5Y)
-43.7%
5-Year Horizon
Sharpe Ratio
0.67
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +94.2%
3 Years 41.0% -43.7% 1.51 +64.5%
5 Years 42.8% -43.7% 0.67 +31%
10 Years 47.6% -86.3% -0.08 -1.4%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Critical leverage: Debt-to-Equity is at 218%.
🔴 High valuation risk: Avg P/E of 68.5 (Elevated multiple compression risk)
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (42.8% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -86.3% in the extended horizon.
ende